卡培他滨和替吉奥作为晚期胃癌一线诱导化疗后维持治疗的临床观察

Clinical observation of capecitabine and tegafur as maintenance therapy after first-line induction chemotherapy for advanced gastric cancer

目的探讨晚期胃癌一线诱导化疗后维持治疗患者实施卡培他滨和替吉奥治疗的效果。方法时间段:2016年5月至2018年4月,研究对象:100例本院接收的晚期胃癌一线诱导化疗后维持治疗患者,按随机表法将其分为实验组(n=50)、对照组(n=50),对照组:卡培他滨维持治疗,实验组:替吉奥维持治疗,分析临床效果、不良反应发生率、生存期、疾病进展期、肿瘤控制率、生活质量。结果实验组临床效果(82.00%vs 70.00%)、不良反应发生率、生存期(15.49±15.53 vs 13.32±15.74)个月、疾病进展期(8.58±9.32 vs 7.71±9.24)个月、肿瘤控制率(88.00%vs 86.00%)、生活质量与对照组相比,差异无统计学意义。结论晚期胃癌一线诱导化疗后维持治疗患者实施卡培他滨和替吉奥治疗的效果无明显差异,均可适当延长患者的疾病进展期,值得临床借鉴和推广。

Objective To investigate the effect of capecitabine and tegafur in patients with advanced gastric cancer after first-line induction chemotherapy.Methods Time period: May 2016 to April 2018,subjects: 100 patients who underwent first-line induction chemotherapy for advanced gastric cancer received by our hospital,were randomly divided into experimental groups (n=50) and the control group (n=50).The control group: capecitabine maintenance treatment,the experimental group: Teggio maintenance treatment,analysis of clinical effects,adverse reaction rate,survival,disease progression.Results The clinical effect of the experimental group (82.00% vs 70.00%),the incidence of adverse reactions,survival (15.49±15.53 vs 13.32±15.74) months,disease progression (8.58±9.32 vs 7.71±9.24) months,tumor control rate (88.00% vs 86.00%),the quality of life was no significant difference compared with the control group.Conclusion There is no significant difference in the efficacy of capecitabine and tegafur in patients with advanced gastric cancer after first-line induction chemotherapy.It is suitable for prolonging the disease progression of patients,which is worthy of clinical reference and promotion.